NAC [Discontinued] by Integrative Therapeutics

NatMed Pro Brand Evidence-based Rating (NMBER)

Product Information hide details

Serving Size 1 Capsule(s)

Ingredients	Amount per capsule
NAC (N-Acetyl L-Cysteine)	600 mg

Other Ingredients

Gelatin Capsule (Form: Gelatin, and Water), Rice Flour

hide details

Editor's Comments hide details

This product has been discontinued by the manufacturer.

hide details

Effectiveness view details

Below is general information about the effectiveness of the known ingredients contained in the product NAC. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.

N-ACETYL CYSTEINE (NAC) (NAC)

EFFECTIVE

Acetaminophen poisoning. Oral and intravenous N-acetyl cysteine, as prescription drug products, are effective for treating acetaminophen poisoning. Details: Administering prescription N-acetyl cysteine orally or intravenously is effective in decreasing mortality rate and preventing the permanent sequelae of acetaminophen poisoning (17,64513,64745,64746). N-acetyl cysteine injection and oral effervescent tablets are approved by the US FDA for this use (102147,104164).
Atelectasis. When inhaled, N-acetyl cysteine is effective for treating atelectasis. Details: N-acetyl cysteine solution for inhalation is effective for atelectasis caused by mucus obstruction (15,91650) and is approved by the US FDA for this use (102147).
Bronchial diagnostic studies. When inhaled, N-acetyl cysteine is effective for bronchial diagnostic study preparation. Details: N-acetyl cysteine solution for inhalation is helpful when used to prepare people for bronchial diagnostic studies (15,91650), and is approved by the US FDA for this use (102147).
Tracheostomy care. When inhaled and used as adjunct therapy, N-acetyl cysteine is effective for preventing endotracheal crusting in patients with a tracheostomy. Details: N-acetyl cysteine solution for inhalation is effective when used as an adjunct for preventing endotracheal crusting in tracheostomy care (15), and is approved by the US FDA for this use (102147).

POSSIBLY EFFECTIVE

Angina. Oral or intravenous N-acetyl cysteine may reduce nitroglycerin tolerance in patients with angina. However, some studies suggest that N-acetyl cysteine might increase the risk for severe headaches and hypotension when used with intravenous or transdermal nitroglycerin. Details: Administering N-acetyl cysteine orally or intravenously, in combination with nitroglycerin, seems to improve unstable angina pectoris (2245,2246). There is also some clinical research showing that concurrent intravenous or oral administration of N-acetyl cysteine reduces the development of nitroglycerin tolerance (832,2245,64546). However, other research shows that taking N-acetyl cysteine orally does not reduce the development of nitroglycerin tolerance in angina patients (2281,2282). Additionally, severe headache and hypotension can occur when oral N-acetyl cysteine and nitroglycerin are administered together, which may limit the feasibility of concomitant use (2245).
Autism spectrum disorder. Oral N-acetyl cysteine may improve irritability, but not other symptoms, associated with autism spectrum disorder. Details: One small clinical study in children with autism shows that taking N-acetyl cysteine 900 mg daily for 4 weeks followed by 900 mg twice daily for 4 weeks and then 900 mg three times daily for 4 weeks improves symptoms of irritability when compared with placebo (91241). Another small clinical study in children and adolescents with autism shows that taking N-acetyl cysteine 1200 mg daily plus risperidone for 8 weeks is more effective than risperidone alone for reducing irritability (91239). However, it does not seem to improve other symptoms, such as hyperactivity, social withdrawal, lethargy, repetitive behaviors, and inappropriate speech (91239,91241,97047).
Bronchitis. Via inhalation, N-acetyl cysteine is FDA-approved for managing acute episodes of bronchitis. Oral N-acetyl cysteine may help to reduce the occurrence of acute exacerbations of chronic bronchitis when used for 3-36 months. Details: N-acetyl cysteine solution for inhalation is FDA-approved for the management of acute bronchopulmonary disease, including bronchitis (102147). Taking N-acetyl cysteine 1200-1500 mg daily orally for 4 months seems to reduce shortness of breath and coughing, and improve lung capacity, in patients with sulfur mustard-induced bronchitis (64586,64614). Also, taking N-acetyl cysteine orally, usually 400-600 mg daily, seems to reduce the risk of acute exacerbations of chronic bronchitis by a moderate amount when used for 3-36 months (6176,64419,102660). Symptom improvement has been shown to occur in 61% of patients taking N-acetyl cysteine, compared with 34% of those taking placebo (102660). However, oral N-acetyl cysteine does not seem to have a beneficial effect on chronic bronchitis when administered for shorter durations (64685,64696,64737,64818).
Chronic obstructive pulmonary disease (COPD). Taking N-acetyl cysteine orally seems to decrease the exacerbation rate and improve symptoms in patients with moderate to severe COPD, particularly those who are not taking inhaled corticosteroids. Also, taking N-acetyl cysteine along with standard therapy appears to improve recovery in patients hospitalized due to an acute exacerbation. Details: N-acetyl cysteine solution for inhalation is FDA-approved for the management of chronic bronchopulmonary disease, such as COPD (102147). A meta-analysis of 12 clinical studies involving 2,691 patients shows that N-acetyl cysteine, given as 257-1800 mg daily for at least 6 months, decreases the number of patients experiencing at least one COPD exacerbation by 15% when compared with placebo; however, it is not associated with a reduction in COPD exacerbation rate or improvement in measures of lung function (97046). Some smaller studies have shown a higher improvement rate of 23% to 40%, with the greatest efficacy seen in patients who are not already taking inhaled corticosteroids (10429,64552). While some studies have failed to show any benefit of N-acetyl cysteine, the lack of benefit appears to correlate with a treatment duration of less than 6 months (64704,97039,97046). The 2015 guidelines from the American College of Chest Physicians and Canadian Thoracic Society (AECOPD) recommend that N-acetyl cysteine be considered as an adjunctive treatment option for patients with moderate to severe COPD and a history of 2 or more exacerbations in the previous 2 years (97043). The 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline also states that N-acetyl cysteine may be an appropriate treatment option for patients who are not able to use inhaled corticosteroids (97050). In hospitalized patients with an acute exacerbation of COPD, preliminary clinical research shows that adding N-acetyl cysteine 1200 mg daily to regular treatment has a moderate effect on wheeze and the need for oxygen over a 7-day period when compared with regular treatment alone (102653).
Contrast induced nephropathy. Oral or intravenous administration of N-acetyl cysteine seems to prevent contrast induced nephropathy in patients with kidney dysfunction. However, it is not beneficial in those with normal kidney function or diabetes. Details: Large meta-analyses of over 150 clinical studies in patients with reduced kidney function (serum creatinine of 1.2-2.4 mg/dL) show that oral N-acetyl cysteine is more effective than either sodium bicarbonate or saline hydration alone in preventing contrast agent-induced kidney damage after coronary angiography, computed tomography, left heart catheterization, and/or percutaneous coronary intervention. N-acetyl cysteine in combination with sodium bicarbonate appears to have similar efficacy to N-acetyl cysteine monotherapy, with an odds ratio of 0.62-0.67, when compared with hydration alone. Pretreatment with high-dose statin, prostaglandin, or theophylline appears to be more effective than N-acetyl cysteine, with odds ratios of 0.37, 0.37, and 0.48, respectively, when compared with hydration alone. However, combination treatment with N-acetyl cysteine and a high-dose statin appears to provide the greatest benefit of all treatments studied, with an odds ratio of 0.31, when compared with hydration alone. No treatments demonstrate significant efficacy in reducing the risk of contrast induced nephropathy in patients with diabetes (97036,97038). Some evidence also suggests that N-acetyl cysteine may have similar effects to fenoldopam in reducing the risk of contrast induced nephropathy in patients with reduced kidney function (64489,97036,97038). N-acetyl cysteine does not reduce the risk of contrast induced nephropathy in patients with normal kidney function (mean serum creatinine less than 1.2 mg/dL) when compared with control (64538,64573,64617). Although many individual studies have failed to show a significant benefit (11430,64514,64543,64561,64581,64623,64639,91232,91236,106884), pooled evidence from these and many additional studies provide a benchmark for the place for N-acetyl cysteine in reducing the risk of contrast induced kidney damage in people with reduced kidney function.
Hyperhomocysteinemia. Oral N-acetyl cysteine seems to reduce homocysteine levels. Details: Taking N-acetyl cysteine orally seems to reduce homocysteine levels in patients with elevated homocysteine levels, including those with kidney failure requiring dialysis (2258,64542,64596).
Hyperlipidemia. Oral N-acetyl cysteine seems to reduce lipoprotein(a) levels. Details: Taking N-acetyl cysteine orally seems to modestly reduce lipoprotein(a) levels in patients with hyperlipidemia (2256,2257,64516).
Ifosfamide (Ifex) toxicity. Oral N-acetyl cysteine may be beneficial for reducing ifosfamide toxicity, although it does not appear to be as effective as mesna. Details: Taking N-acetyl cysteine orally seems to reduce ifosfamide-induced bladder toxicity (5808,10270,64730). However, mesna seems to be more effective for preventing ifosfamide toxicity than N-acetyl cysteine (10748).
Influenza. Oral N-acetyl cysteine may reduce the risk for symptomatic influenza. Details: One multi-center clinical trial conducted in Italy shows that taking N-acetyl cysteine 600 mg twice daily for 6 months does not prevent influenza infection, but reduces the risk for clinically apparent disease by 68%, when compared with placebo (2260).
Kidney failure. Oral N-acetyl cysteine may reduce the risk for cardiovascular events in patients with kidney failure. Details: One clinical study in adults with kidney failure who have been on dialysis for at least 3 months shows that taking N-acetyl cysteine 600 mg twice daily reduces the incidence of cardiovascular events, such as ischemic stroke and myocardial infarction, by about 40% when compared with placebo. There was no effect on total mortality or mortality from cardiovascular causes, although the study may have been inadequately powered to detect a difference in these outcomes (10430).
Myocardial infarction (MI). Intravenous N-acetyl cysteine, along with standard therapy, seems to improve outcomes in patients with MI. Oral N-acetyl cysteine has not been evaluated for this use. Details: Clinical research in adults undergoing percutaneous coronary intervention (PCI) for ST-segment elevation MI shows that administering N-acetyl cysteine with nitroglycerin as a continuous intravenous infusion for 48 hours reduces myocardial infarct size by 5.5%, doubles the extent of myocardial salvage, and shortens the time to chest pain resolution when compared with nitroglycerin plus placebo (97044). Additional preliminary clinical research shows that intravenous N-acetyl cysteine, when given with nitroglycerin and streptokinase in patients with evolving MI, may preserve left ventricular function and reduce oxidative stress (7872,64502,64778).

POSSIBLY INEFFECTIVE

Amyotrophic lateral sclerosis (ALS, Lou Gehrig's disease). Subcutaneous administration of N-acetyl cysteine does not seem to improve survival or disease progression in patients with ALS. Details: One clinical trial in patients with ALS shows that administering N-acetyl cysteine 50 mg/kg daily for 12 months via subcutaneous injection does not improve survival or slow disease progression when compared with placebo (2254).
Anthracycline cardiotoxicity. Oral N-acetyl cysteine does not seem to prevent or treat doxorubicin-induced cardiac toxicity. Details: Small clinical studies show that taking N-acetyl cysteine orally does not seem to prevent or reverse doxorubicin-induced cardiac toxicity when compared with placebo or a control group (2252,2253,64712).
Bronchopulmonary dysplasia. Intratracheal N-acetyl cysteine does not seem to prevent bronchopulmonary dysplasia in premature infants. Details: Clinical research in premature infants shows that intratracheal N-acetyl cysteine does not seem to improve symptoms, hasten recovery of chronic lung disease, or reduce the risk of bronchopulmonary dysplasia when compared with placebo (64460,64490).
Cannabis use disorder. Oral N-acetyl cysteine does not seem to improve abstinence rates in patients with cannabis use disorder. Details: Most clinical research in adolescents and adults with cannabis use disorder shows that taking N-acetyl cysteine 1200 mg twice daily for 8-12 weeks as an adjunct to counseling and other interventions does not reduce symptoms of depression or help with cannabis abstinence (99531,102663,102666,102668). Although a single study shows that taking N-acetyl cysteine more than doubles the odds of a negative urine cannabinoid test over an 8-week period in adolescents aged 15-21 when compared with placebo, there was no significant difference in the time to first negative urine cannabinoid test or end of treatment abstinence (102666).
Cystic fibrosis. Oral or inhaled N-acetyl cysteine does not seem to improve lung function in patients with cystic fibrosis. Details: Most clinical research shows that taking oral or nebulized N-acetyl cysteine does not significantly improve lung function or lung capacity in patients with cystic fibrosis when compared with a control (22735,64406,64671,64743). However, one preliminary clinical study shows that high-dose oral N-acetyl cysteine reduces the number and activity of airway neutrophils in these patients when compared with placebo (64510).
Erythropoietic protoporphyria (EPP). Oral N-acetyl cysteine does not seem to improve photosensitivity in patients with EPP. Details: Small clinical studies show that taking N-acetyl cysteine 1800 mg daily orally for 4 weeks does not improve photosensitivity in patients with EPP when compared with placebo or baseline (64448,64756).
Helicobacter pylori. Adding oral N-acetyl cysteine to conventional Helicobacter pylori (H. pylori) eradication regimens does not seem to increase eradication rates. Details: Despite conflicting findings from individual, small clinical studies (64497,97042), meta-analyses of clinical research show that adding N-acetyl cysteine to a standard antibiotic eradication regimen does not improve eradication when compared with standard eradication therapy alone (99530,106901). N-acetyl cysteine has also been evaluated in combination with other ingredients. Preliminary clinical research shows that taking N-acetyl cysteine 600 mg orally twice daily in combination with curcumin 30 mg, bovine lactoferrin 100 mg, and pantoprazole 20 mg, all taken twice daily for one week, without antibiotic therapy does not eradicate H. pylori infection, although it might improve dyspeptic symptoms and gastrointestinal inflammation (64559).
Hepatitis. Oral N-acetyl cysteine does not appear to improve treatment response in patients with hepatitis. However, when taken with interferon, it might lengthen the time to relapse. Details: Taking N-acetyl cysteine orally does not seem to benefit patients with acute viral hepatitis (64462). Also, adding N-acetyl cysteine to conventional interferon therapy does not seem to improve treatment response in patients with hepatitis C when compared with interferon therapy alone (64418,64799,64825). However, some clinical research shows that adding N-acetyl cysteine to interferon therapy delays relapse in hepatitis C patients when compared with interferon treatment alone (64424).
HIV/AIDS. Oral N-acetyl cysteine does not seem to increase CD4+ cell count in patients with HIV. Details: Small clinical studies show that taking N-acetyl cysteine 400 mg orally twice daily or 600 mg once daily for 4-6 months does not improve CD4+ cell counts or viral load in patients with HIV when compared with placebo (64482,64779). In addition, taking N-acetyl cysteine 600 mg orally three times daily in combination with sodium selenite 500 mcg daily for up to 24 weeks does not affect the percentage of CD4+ lymphocytes or viral load in HIV patients when compared with a control (64798).
Hypotension. Oral N-acetyl cysteine does not seem to improve renal outcomes in patients with prolonged hypotension. Details: One clinical trial in patients with prolonged hypotension shows that taking N-acetyl cysteine orally for 7 days does not reduce the risk of acute kidney failure when compared with placebo (64545).
Infertility. Oral N-acetyl cysteine does not seem to improve fertility in females with unexplained infertility. Details: One clinical trial in females with unexplained infertility shows that taking oral N-acetyl cysteine 1200 mg daily in addition to clomiphene citrate 50 mg twice daily for 5 days, beginning on the second day of the cycle, does not improve pregnancy rate or reduce miscarriage rate when compared with clomiphene citrate alone (64528).
Liver transplant. Intravenous N-acetyl cysteine during liver donor operation does not seem to improve liver transplant outcomes. Oral N-acetyl cysteine has not been evaluated for this use. Details: One clinical trial shows that administering N-acetyl cysteine intravenously during a liver donor operation and preserving the liver in cold solution containing N-acetyl cysteine does not reduce the risk of ischemia reperfusion injury or acute cellular rejection in liver transplant recipients when compared with control (64486).
Pancreatitis. Oral N-acetyl cysteine does not seem to prevent pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP). Additionally, intravenous N-acetyl cysteine does not seem to reduce the risk of organ dysfunction in patients being treated for severe acute pancreatitis. Details: Two clinical trials show that taking oral N-acetyl cysteine 1200 mg once before undergoing ERCP does not reduce the risk of post-ERCP pancreatitis when compared with placebo (64522,109939). One of these trials also evaluated oral N-acetyl cysteine in combination with rectal indomethacin, but the incidence of post-ERCP pancreatitis did not appear to be lower when compared with taking indomethacin alone. However, the study may have been inadequately powered to detect a difference between those groups (109939). In patients with severe acute pancreatitis, intravenous N-acetyl cysteine, in combination with selenium and vitamin C, also does not seem to reduce the risk of organ dysfunction (64551).
Postoperative recovery. Oral or intravenous N-acetyl cysteine does not seem to improve survival, prevent complications, or reduce length of hospital stay in patients undergoing cardiac or liver surgery. Details: N-acetyl cysteine, taken orally or intravenously, does not seem to reduce the risk of myocardial infarction, stroke, kidney injury, or mortality or reduce the length of hospital stay following cardiac surgery (64610,64624,64628,64635,91233,91240). While some meta-analyses of clinical research show that taking N-acetyl cysteine orally or intravenously reduces the odds of postoperative atrial fibrillation by 36% to 44% when compared with placebo in patients undergoing cardiac surgery (64635,91233,91240), conflicting results exist (64624). In patients undergoing liver resection, intravenous N-acetyl cysteine does not reduce complication rate, risk of liver failure, length of hospital stay, or mortality when compared with a control group. In fact, patients receiving N-acetyl cysteine were more likely to experience delirium and its associated complications (99532).

LIKELY INEFFECTIVE

Head and neck cancer. Oral N-acetyl cysteine does not seem to reduce mortality, improve event-free survival, or prevent additional tumors in patients with head and neck cancer. Details: Taking N-acetyl cysteine orally does not prevent second primary tumors in patients with head and neck cancer (1710). Also, N-acetyl cysteine alone, or in combination with retinyl palmitate, has no effect on mortality or event-free survival in these patients (1710).
Lung cancer. Oral N-acetyl cysteine does not seem to reduce mortality, improve event-free survival, or prevent additional tumors in patients with lung cancer. Details: Taking N-acetyl cysteine orally does not prevent second primary tumors in patients with lung cancer (1710). Also, N-acetyl cysteine alone, or in combination with retinyl palmitate, has no effect on mortality or event-free survival in these patients (1705,1710).
Multisystem organ failure. Administering intravenous N-acetyl cysteine might increase the risk of mortality due to multisystem organ failure. Oral N-acetyl cysteine has not been evaluated for this use. Details: Administering N-acetyl cysteine intravenously, greater than 24 hours after hospital admission, might increase mortality rate due to multisystem organ failure. The effect of N-acetyl cysteine given within 24 hours of hospital admission requires further study (7871).

INSUFFICIENT RELIABLE EVIDENCE to RATE

Acute respiratory distress syndrome (ARDS). Research on the use of intravenous N-acetyl cysteine in patients with ARDS is conflicting. Oral N-acetyl cysteine has not been evaluated for this purpose. Details: Some clinical research shows that N-acetyl cysteine might reduce mortality and improve oxygenation in patients with acute lung injury/ARDS when compared with a control (64619). These patients were administered intravenous N-acetyl cysteine 150 mg/kg on the first day followed by 50 mg/kg for 3 more days. However, other clinical research shows that administering intravenous N-acetyl cysteine 40 mg/kg daily for 3 days does not reduce the risk of ARDS development in patients with acute lung injury (64771). Also, some clinical research shows that intravenous N-acetyl cysteine for up to 6 days does not reduce the time for improvement in patients with ARDS (64492). These discrepancies may be due to variations in genes involved in glutathione-S-transferase (GST) expression (64619).
Adrenoleukodystrophy (ALD). It is unclear if oral or intravenous N-acetyl cysteine is beneficial in patients with ALD. Details: A case series of three male children with this rare condition suggests that administering N-acetyl cysteine orally and intravenously might improve overall survival and stabilize neurologic status after hematopoietic stem cell transplantation when compared with historical controls (64547).
Aging. Oral N-acetyl cysteine has only been evaluated in combination with other ingredients; its effect when used alone is unclear. Details: Preliminary clinical research in older adults shows that taking a combination product containing N-acetyl cysteine 100 mg/kg, glycerine 100 mg/kg, and alanine 200 mg/kg orally daily for 16 weeks modestly improved waist circumference, systolic blood pressure, and some serum markers of oxidative stress, but not body-mass index or diastolic blood pressure, when compared with placebo (110624). It is unclear if this effect is due to N-acetyl cysteine, other ingredients, or the combination.
Alcohol-related liver disease. Although there has been interest in using oral N-acetyl cysteine for preventing alcohol-related liver damage, there is insufficient reliable information about the clinical effects of N-acetyl cysteine for this purpose.
Allergic rhinitis (hay fever). Although there has been interest in using oral N-acetyl cysteine for allergic rhinitis, there is insufficient reliable information about the clinical effects of N-acetyl cysteine for this condition.
Altitude sickness. It is unclear if oral N-acetyl cysteine can treat or prevent altitude sickness. Details: One very small clinical trial shows that taking N-acetyl cysteine 400 mg daily does not reduce altitude-associated anorexia or improve food intake in individuals exposed to high altitudes when compared with either placebo or vitamin E 400 mg daily (64599).
Alzheimer disease. It is unclear if oral N-acetyl cysteine is beneficial for Alzheimer disease. Details: One clinical trial in a small number of patients with Alzheimer disease shows that taking N-acetyl cysteine 50 mg/kg daily for 6 months does not improve most cognitive symptoms of Alzheimer disease when compared with placebo (7870). However, preliminary clinical research in adults with mild to moderate Alzheimer disease also shows that taking a combination product containing N-acetyl cysteine 2.55 grams, L-serine 12.35 grams, nicotinamide riboside 1 gram, and L-carnitine tartrate 3.73 grams orally once daily for 28 days followed by twice daily for 56 more days improves cognitive functioning scores by 14% to 29% when compared with placebo (110623). It is unclear if this effect is due to N-acetyl cysteine, other ingredients, or the combination.
Aminoglycoside ototoxicity. Small clinical studies suggest that oral N-acetyl cysteine may modestly reduce the risk of ototoxicity caused by aminoglycoside therapy. Details: A meta-analysis of available clinical research in adults with kidney failure receiving aminoglycosides for bloodstream infections shows that taking N-acetyl cysteine 600 mg twice daily for a total of 14 days, or for up to 7 days after completion of aminoglycoside therapy, reduces the risk of hearing loss by 33% when compared with placebo. The findings of this analysis are limited by the small sample sizes and high risk of bias of the included studies (97049).
Asthma. It is unclear if inhaling N-acetyl cysteine is beneficial in patients with asthma. Details: Preliminary clinical research shows that, when administered as an aerosol daily for one week in combination with isoproterenol, N-acetyl cysteine 10% improves lung capacity and decreases sputum viscosity when compared with placebo in patients with asthma (64674).
Athletic performance. It is unclear if oral N-acetyl cysteine can improve athletic performance. Details: Some small clinical studies shows that N-acetyl cysteine might be beneficial if taken orally at a dose of 1200 mg daily for 9 days leading up to exercise or when administered intravenously both before and during exercise (64529,91248), but that it might not improve performance when taken as a single 20 mg/kg oral dose 60 minutes prior to exercise (102028).
Biliary disorders. It is unclear if intravenous N-acetyl cysteine is beneficial in patients with biliary disorders. Oral N-acetyl cysteine has not been evaluated for this use. Details: Preliminary clinical research in patients undergoing surgical bypass for obstructive jaundice shows that postoperative intravenous N-acetyl cysteine for 48 hours reduces levels of some liver enzymes, but not bilirubin levels or mean hospital stay, when compared with a control group. Although all liver enzyme levels had not returned to normal by 30 days after surgery, they were more improved in the group using N-acetylcysteine (102654).
Bipolar disorder. The effects of oral N-acetyl cysteine in patients with bipolar disorder are conflicting. Oral N-acetyl cysteine might reduce symptoms of depression and increase remission rates, but it does not appear to be beneficial for reducing symptoms of mania or for maintaining remission. Details: One clinical study in patients with bipolar disorder shows that taking N-acetyl cysteine 1000 mg twice daily as adjunct to usual therapy for 24 weeks reduces symptoms of depression when compared with placebo (64608). A subgroup analysis of patients from this study who were diagnosed with bipolar II disorder shows that this dose of N-acetyl cysteine can increase the number of patients who achieve remission of both depression and mania, but not the number achieving remission of only one of these, when compared with placebo (91243). However, other research shows that taking N-acetyl cysteine 3 grams daily in addition to standard therapy for 20 weeks does not improve depression when compared with placebo in patients with bipolar depression experiencing a depressive episode for at least 4 weeks. A limitation of this study is the high (56%) placebo response rate, which might have limited the ability to detect between-group differences in symptoms improvements (99529). Taking N-acetyl cysteine as an adjunct to usual therapy does not appear to be beneficial for maintaining remission. A clinical study in patients with bipolar disorder shows that, although taking N-acetyl cysteine 1000 mg twice daily for 8 weeks improves symptoms of bipolar disorder when compared to baseline, maintenance therapy with N-acetyl cysteine for an additional 6 months does not improve depression symptoms or prevent recurrence when compared with placebo (91234).
Bronchiectasis. Oral N-acetyl cysteine has been evaluated in patients with bronchiectasis, with promising results. Details: Preliminary clinical research in Chinese adults with bronchiectasis shows that taking N-acetyl cysteine 600 mg twice daily for 12 months reduces the risk of exacerbation by 59% when compared with a control group receiving on-demand treatment only. For every eight patients treated with N-acetyl cysteine, one additional patient was free of exacerbations at 12 months when compared with on-demand treatment only (102027).
Canker sores. It is unclear if rinsing the mouth with N-acetyl cysteine solution is beneficial in patients with canker sores. Details: Preliminary clinical research in patients with recurrent canker sores shows that rinsing the mouth with N-acetyl cysteine (ACC, HEXAL AG) 200 mg dissolved in water for 30 seconds is no more effective than 0.12% chlorhexidine digluconate for canker sore healing time or level of pain. However, pain was reduced by 50% to 90% more over baseline 2-4 days after use of N-acetyl cysteine when compared with 0.12% chlorhexidine digluconate (102659).
Chemotherapy-induced hepatotoxicity. It is unclear if intravenous N-acetyl cysteine is beneficial in patients with chemotherapy-induced hepatotoxicity. Oral N-acetyl cysteine has not been evaluated for this use. Details: Some observational research in children aged 2-17 years with chemotherapy-induced hepatotoxicity has found that intravenous N-acetyl cysteine 3 mcg/kg over 24 hours is associated with day-to-day improvement in liver injury, based on liver function enzyme levels, when compared with no N-acetyl cysteine therapy. Decreases in liver enzymes also occurred earlier in patients using N-acetyl cysteine (102664).
Chemotherapy-induced peripheral neuropathy. Small clinical studies suggest that oral N-acetyl cysteine may reduce the risk for peripheral neuropathy in patients receiving oxaliplatin. Details: One preliminary clinical study in patients with colon cancer shows that taking N-acetyl cysteine 1200 mg orally at 1.5 hours prior to oxaliplatin therapy reduces the incidence of oxaliplatin-induced neuropathy when compared with placebo (64505). Another small clinical trial in patients with gastric or colorectal cancers shows that taking N-acetyl cysteine (Osveh Pharmaceutical Company) 1200 mg one hour before receiving oxaliplatin during eight courses of chemotherapy reduces the incidence and severity of neurotoxicity symptoms when compared with placebo. In patients taking N-acetyl cysteine, 31% had no signs of neurotoxicity after oxaliplatin chemotherapy, compared with 0% of those taking placebo. Also, 44% had mild symptoms, compared with 6% of those taking placebo. However, there were no significant differences in electrophysiological sensory results (102665).
Chronic fatigue syndrome (CFS). Although there has been interest in using oral N-acetyl cysteine for CFS, there is insufficient reliable information about the clinical effects of N-acetyl cysteine for this purpose.
Chronic kidney disease (CKD). Oral N-acetyl cysteine does not seem to improve kidney function in patients with CKD or reduce the risk of kidney injury or other complications after cardiac surgery in patients with CKD. However, intravenous N-acetyl cysteine might offer some benefit in patients with CKD undergoing cardiac surgery. Details: Clinical research shows that taking N-acetyl cysteine 1200 mg orally daily in combination with standard antihypertensive drugs does not reduce proteinuria or other markers of kidney injury in patients with CKD (64627). N-acetyl cysteine has also been evaluated for the prevention of acute kidney injury following cardiac surgery in patients with CKD, with conflicting results. Several meta-analyses have shown that N-acetyl cysteine does not reduce the incidence of acute kidney injury, postoperative complications, postoperative interventions, length of hospitalization, or mortality after cardiac surgery in adults with CKD (95766,95767,95768). However, these meta-analyses found that intravenous, but not oral, N-acetyl cysteine might be beneficial (95767,95768). A more recent meta-analysis shows that intravenous N-acetyl cysteine reduces the risk of postoperative acute kidney injury by 23% and reduces the risk of cardiac adverse events by 17% (99533). However, most of the studies included in this latter meta-analysis were small and the definition of cardiac events varied among the included studies. Higher quality research is needed to determine the benefit, if any, of N-acetyl cysteine in reducing acute kidney injury after cardiac surgery in patients with CKD.
Cocaine dependence. It is unclear if oral N-acetyl cysteine is effective for reducing cravings or withdrawal symptoms in people trying to stop cocaine use. Details: Some preliminary clinical research shows that taking N-acetyl cysteine 600 mg twice daily for 2 days reduces the desire to use cocaine when compared with placebo in individuals with cocaine dependence (64563). However, other preliminary clinical research shows that taking oral N-acetyl cysteine 600 mg twice daily for 2 days does not reduce cravings or withdrawal symptoms when compared with placebo in patients hospitalized for cocaine dependency (64504).
Colorectal cancer. It is unclear if oral N-acetyl cysteine is effective for preventing colorectal cancer. Details: Clinical research in a small group of patients with a history of adenomatous colonic polyps shows that taking N-acetyl cysteine 800 mg daily for 12 weeks reduces the proliferative index of colonic crypts, suggesting that N-acetyl cysteine might decrease the likelihood of colorectal cancer (7873).
Coronary artery bypass graft (CABG) surgery. It is unclear if oral or intravenous N-acetyl cysteine is beneficial in patients undergoing CABG surgery. Details: A small clinical study shows that taking N-acetyl cysteine 300 mg orally in addition to intermittent blood cardioplegia does not affect postoperative outcomes or the risk of mortality when compared with control in patients undergoing elective CABG surgery (64638). Another small clinical study shows that giving N-acetyl cysteine 100 mg/kg by intravenous infusion, for two doses during CABG surgery and one postoperative dose, seems to reduce serum creatinine levels at 4 and 48 hours after surgery and reduce the incidence of acute kidney injury when compared with placebo. However, serum creatinine levels were within the normal range in all patients (106886).
Coronavirus disease 2019 (COVID-19). Small clinical trials suggest that intravenous N-acetyl cysteine is not beneficial in patients at risk for respiratory failure from severe COVID-19. It is unclear if oral use is beneficial. Details: A small single-center clinical trial of patients presenting to the emergency room with COVID-19 pneumonia in Brazil shows that receiving intravenous N-acetyl cysteine 21 grams in dextrose 5% over 20 hours in conjunction with institutional standard care, including empiric antibiotics, does not reduce the need for mechanical ventilation, length of intensive care unit (ICU) stay, or mortality when compared with dextrose 5% (105560). Another small single-center clinical trial in patients with COVID-19 and acute respiratory distress syndrome (ARDS) in Iran shows that receiving a continuous intravenous infusion of N-acetyl cysteine 40 mg/kg in dextrose 5% daily for 3 days in conjunction with institutional standard care, including corticosteroids, vitamin C, vitamin D, and zinc, also does not reduce the need for mechanical ventilation, length of ICU stay, or mortality when compared with dextrose 5% (105561). Similarly, a retrospective study of patients hospitalized in Italy for COVID-19 pneumonia shows that receiving intravenous N-acetyl cysteine 300 mg three times daily, switched to 600 mg twice daily if the patient was clinically stable, for a duration of least 5 days, does not improve inpatient mortality, ICU admission, length of ICU stay, or the incidence of atelectasis, when compared with no supplementation. At a 6-month follow-up, treatment with N-acetyl cysteine also did not appear to impact long-term outcomes in these patients (108449). In contrast, a small, retrospective study in hospitalized patients with moderate to severe COVID-19 pneumonia shows that taking oral N-acetyl cysteine, 600 mg twice daily for 10 days in addition to standard care, including empiric antibiotics, corticosteroids, and remdesivir, reduces the risk for severe respiratory failure requiring ventilator support and reduces mortality at 14 days in those with severe pneumonia when compared with standard care alone (106885). Prospective, randomized, double-blind trials are needed to confirm these findings.
Dental plaque. It is unclear if mouthwash solutions containing N-acetyl cysteine can reduce dental plaque; higher concentrations may be more effective than lower concentrations. Details: Preliminary clinical research shows that using a mouthwash solution containing N-acetyl cysteine 10% four times daily for 7 days reduces dental plaque (64687). However, other clinical research shows that rinsing twice daily for 3 weeks with N-acetyl cysteine 1.25% does not reduce the development of plaque. In addition, N-acetyl cysteine 1.25% was not beneficial when used for 2 weeks as a treatment for experimental plaque (102662).
Dry eye. Small clinical studies suggest that eye drops containing N-acetyl cysteine, with or without chitosan, might improve objective measures of dry eye. Details: Preliminary clinical research in patients with dry eye shows that using tear solution containing 20% N-acetyl cysteine every two hours for 2 months improves objective, but not subjective, symptoms of dry eye syndrome when compared with artificial tears (64705). A small clinical study in patients with moderate to severe dry eye disease shows that applying a specific product (Lacrimera) containing chitosan-N-acetyl cysteine as one drop once or twice daily improves tear film thickness (TFT) after 10 minutes of application, and is maintained for 24 hours, when compared with placebo. Once or twice daily application does not seem to alter the level of benefit (97710). It is unclear if the benefit of this combination product is due to N-acetyl cysteine, chitosan, or the combination.
Endometriosis. Oral N-acetyl cysteine has only been evaluated in combination with other ingredients; its effect when used alone is unclear. Details: Preliminary clinical research in adults with endometriosis-associated pelvic pain shows that taking a combination product containing N-acetyl cysteine 1200 mg, alpha lipoic acid 400 mg, bromelain 50 mg, and zinc 20 mg daily for 6 months improves pain and reduces analgesic intake when compared to baseline (99535). This study was limited by a lack of comparator group.
Esophagogastroduodenoscopy (EGD). It is unclear if N-acetyl cysteine (NAC) can improve visualization when used as a premedication for EGD. Details: Clinical research shows that giving NAC orally, 600 mg in 90 mL of an emulsion formulation, 20 minutes prior to EGD reduces foaming and mucus, allowing better visualization of the mucosa. The percentage of patients with no bubbles affecting visualization is about 51% with NAC, compared with 34% with placebo. The percentage not requiring suction or endoscopic flushes is 50% with NAC and 27% with placebo. Giving simethicone 150 mg in combination with NAC further improves visualization (108941).
Exercise-induced muscle damage. It is unclear if oral N-acetyl cysteine is effective for preventing or treating exercise-induced muscle damage. Details: One small clinical study shows that taking N-acetyl cysteine 20 mg/kg daily in three divided doses after muscle-damaging exercise does not improve muscle repair or inflammatory response in healthy patients taking part in a specific resistance training program (91244).
Fibrocystic breast disease. It is unclear if oral N-acetyl cysteine is effective for fibrocystic beast disease. Details: Preliminary clinical research in adult females with fibrocystic breast disease and cyclical mastalgia shows that taking N-acetyl cysteine (Osvah Pharmaceutical Company) 600 mg orally once daily for 12 weeks modestly improves pain scores when compared with placebo (109938).
Gingivitis. It is unclear if mouthwash containing N-acetyl cysteine is effective for the prevention or treatment of gingivitis. Details: Clinical research shows that rinsing twice daily for 3 weeks with N-acetyl cysteine 1.25% is slightly more effective than placebo for reducing the development of gingivitis. However, there was no effect on plaque. In addition, N-acetyl cysteine is not as effective as chlorhexidine 0.2% and had no benefit when used for 2 weeks as a treatment for experimental gingivitis (102662).
Hangover. Although there has been interest in using oral N-acetyl cysteine for treating hangovers, there is insufficient reliable information about the clinical effects of N-acetyl cysteine for this purpose.
Hearing loss. It is unclear if oral N-acetyl cysteine is effective for preventing or treating hearing loss. Details: A meta-analysis of clinical trials in adults shows that taking N-acetyl cysteine 900-2700 mg orally daily for up to 42 days modestly protects against noise-induced hearing loss in middle to high hearing thresholds (0 to 4 kHz and 0 to 6 kHz), but not low hearing thresholds (0 to 2 kHz), when compared with control. However, the validity of this study is limited by high heterogeneity (109937). Another meta-analysis of 2 clinical trials in adults with sudden hearing loss shows that taking N-acetyl cysteine 1200 mg orally daily for 2 weeks to 3 months moderately improves pure tone threshold hearing when compared with control (109940).
Hepatorenal syndrome. It is unclear if intravenous N-acetyl cysteine is beneficial in patients with hepatorenal syndrome. Oral N-acetyl cysteine has not been evaluated for this use. Details: A case series of 12 patients with hepatorenal syndrome reported that intravenous N-acetyl cysteine, starting with a 150 mg/kg loading dose over 2 hours, followed by a continuous infusion of 100 mg/kg daily for 5 days, modestly improved kidney function, but not liver function or blood pressure. When compared with historical controls, N-acetyl cysteine administration was also associated with an improvement in total survival time (1752). Prospective clinical studies are needed to confirm these findings.
Hereditary hemorrhagic telangiectasia (HHT). It is unclear if oral N-acetyl cysteine is beneficial in patients with HHT. Details: One small clinical study shows that taking N-acetyl cysteine 600 mg three times daily orally for 12 weeks decreases the frequency and severity of daytime nosebleeds, but not nighttime nosebleeds, when compared to baseline in individuals with HHT (64643). The validity of these findings is limited by the lack of a comparator group.
Idiopathic interstitial pneumonia. It is unclear if oral or inhaled N-acetyl cysteine is beneficial for the management of various forms of interstitial pneumonia. Details: A very small clinical study in patients with idiopathic interstitial pneumonia shows that taking N-acetyl cysteine 600 mg three times daily for 12 weeks seems to improve pulmonary function tests and decrease biochemical markers of disease when compared with baseline (7868). However, a meta-analysis of clinical research in patients with idiopathic pulmonary fibrosis, a specific type of interstitial pneumonia, shows that oral or inhaled N-acetyl cysteine does not reduce the risk of acute exacerbations or attenuate decline of lung function as measured by forced vital capacity (FVC), when compared with placebo (99538).
Lead toxicity. Although there has been interest in using oral N-acetyl cysteine for lead toxicity, there is insufficient reliable information about the clinical effects of N-acetyl cysteine for this purpose.
Malaria. It is unclear if intravenous N-acetyl cysteine is beneficial as an adjunct in treating malaria. Oral N-acetyl cysteine has not been evaluated for this use. Details: One small clinical study shows that intravenous N-acetyl cysteine, in combination with intravenous artesunate, does not reduce symptoms or the risk of mortality in patients with severe malaria when compared with artesunate alone (64630).
Male infertility. It is unclear of oral N-acetyl cysteine is beneficial for male infertility. Details: Clinical research in adults with idiopathic oligoasthenoteratospermia shows that taking N-acetyl cysteine 600 mg orally daily for 26 weeks improves sperm concentration, but not sperm motility, when compared with placebo (64626). Additionally, a preliminary clinical study in adults with asthenoteratozoospermia shows that taking N-acetyl cysteine 600 mg daily for 3 months improves sperm motility and concentration, increases protamine, and improves hormone levels and sperm morphology when compared to baseline (99534). The validity of this study is limited by the lack of a comparator group. There is also interest in using N-acetyl cysteine to attenuate the infertility effects observed after COVID-19 infection. A large clinical study in males who had normal sperm analysis prior to COVID-19, but with significantly lower sperm parameters within 6 weeks after infection, shows that taking oral N-acetyl cysteine 600 mg daily for 3 months improves sperm volume, concentration, morphology, and total motility when compared with baseline post-COVID-19 levels (108447). Although the study enrolled a control group, the investigators did not provide a statistical comparison of outcomes between groups, limiting the validity of this finding.
Mercury toxicity. Although there has been interest in using oral N-acetyl cysteine for mercury toxicity, there is insufficient reliable information about the clinical effects of N-acetyl cysteine for this purpose.
Miscarriage. Oral N-acetyl cysteine has only been evaluated in combination with other ingredients; its benefit when used alone is unclear. Details: One small clinical trial shows that taking oral N-acetyl cysteine 600 mg daily with folic acid 500 mcg daily improves the likelihood of maintaining pregnancy past 20 weeks when compared with folic acid alone in adults with a history of recurrent pregnancy loss (64616).
Multiple sclerosis (MS). It is unclear if oral and intravenous N-acetyl cysteine are beneficial in patients with MS. Details: One clinical trial in a small group of patients with MS shows that intravenous and oral N-acetyl cysteine in addition to standard care for 2 months improves self-reported cognition by a moderate amount when compared with standard care alone. Self-reported attention also seems to improve (102657).
Nitrate tolerance. Intravenous N-acetyl cysteine seems to reduce the development of nitrate tolerance. Oral N-acetyl cysteine has shown mixed results for this use. Details: Some clinical research shows that concurrent intravenous or oral administration of N-acetyl cysteine reduces the development of nitroglycerin tolerance (832,2245,64546). However, other research suggests that oral N-acetyl cysteine does not reduce the development of nitroglycerin tolerance in patients with angina (2281,2282).
Nonalcoholic steatohepatitis (NASH). It is unclear if oral N-acetyl cysteine is beneficial in patients with NASH. Details: One small clinical study in patients with NASH shows that taking N-acetyl cysteine 1.2 grams with metformin 850-1500 mg daily for 48 weeks reduces NASH activity scores and measures of steatosis and hepatocellular ballooning, but not inflammation or fibrosis, when compared to baseline. However, taking the same dose of N-acetyl cysteine and metformin along with ursodeoxycholic acid 15 mg/kg daily does not improve these outcomes, or improve liver enzyme levels, when compared with baseline (102026). The reasons for these disparate findings are unclear. Inadequate statistical power and the lack of a comparator group limit the validity of these findings.
Obsessive-compulsive disorder (OCD). Oral N-acetyl cysteine might improve some symptoms of OCD when used with fluvoxamine in adults. Its effects when used in combination with other psychiatric medications or as monotherapy in children and adults is unclear. Details: Preliminary clinical research in adults shows that taking N-acetyl cysteine 1000 mg twice daily along with fluvoxamine 200 mg daily for 10 weeks modestly reduces overall symptoms of OCD and symptoms of obsession when compared with fluvoxamine alone. However, the addition of N-acetyl cysteine is not associated with an improvement in symptoms of compulsion, nor with a statistically significant increase in partial or complete responders, when compared with fluvoxamine alone (97048). A clinical trial in adults with OCD who are taking various psychiatric medications shows that adding oral N-acetyl cysteine 2000-4000 mg daily for 20 weeks does not reduce symptoms of OCD, or improve secondary outcomes such as anxiety, mood, functioning, or quality of life, when compared with placebo (108450). Over half (63%) of patients had a comorbid psychiatric diagnosis, limiting the applicability of these findings. Other preliminary clinical research in adults with moderate to severe OCD who are taking various psychiatric medications shows that taking N-acetyl cysteine 3000 mg daily for 16 weeks does not improve OCD symptoms when compared with placebo (97045). A very small preliminary clinical trial in children aged 8-17 years, most of whom are not taking psychiatric medications, shows some benefit for symptom reduction when N-acetyl cysteine 2700 mg daily for 12 weeks is compared with placebo (102656).
Otitis media. Although there has been interest in using ear drops containing N-acetyl cysteine for otitis media, there is insufficient reliable information about the clinical effects of N-acetyl cysteine for this purpose.
Polycystic ovary syndrome (PCOS). Oral N-acetyl cysteine might improve pregnancy-related outcomes in PCOS, although it appears to be less effective than metformin. Evidence on its benefits for other symptoms of PCOS is conflicting. Details: Some research in patients with PCOS shows that N-acetyl cysteine can increase insulin sensitivity, improve hirsutism, and improve menstrual irregularity (64435,64550,91245,102121). It may also improve fasting insulin levels, but results are conflicting (64435,64550,91245). Other research shows that N-acetyl cysteine, alone or as a specific combination product (Ovaric HP, Just Pharma), increases ovulation rates in some, but not all, patients with PCOS (64480,64550,64553,91246,91247,102121). A meta-analysis of clinical research suggests that N-acetyl cysteine increases the odds of having a live birth, getting pregnant, and/or ovulating by about 3-fold when compared with placebo. Its effects on the odds of pregnancy and ovulation appear to be greater in those resistant to clomiphene citrate. However, when compared with metformin, N-acetyl cysteine appears to decrease the odds of getting pregnant by about 60% and decrease the odds of ovulation by about 87%. N-acetyl cysteine also does not appear to reduce the rate of miscarriage, menstrual irregularity, or the severity of acne or hirsutism in people with PCOS (93057). Another meta-analysis shows that N-acetyl cysteine in various doses is associated with an insignificant improvement in ovulation and pregnancy rate, multiple pregnancy rate, and miscarriage rate, and is less efficacious than metformin for all of these outcomes (106888).
Post-traumatic stress disorder (PTSD). It is unclear if oral N-acetyl cysteine is beneficial in veterans with PTSD. Details: A small clinical study in veterans with PTSD and a history of substance use disorders shows that taking N-acetyl cysteine 1200 mg orally twice daily for 8 weeks while receiving cognitive behavioral therapy reduces depressive symptoms and the rate of self-reported PTSD symptoms when compared with cognitive behavioral therapy plus placebo. Additionally, receiving N-acetyl cysteine reduces the amount and frequency of cravings by 81% and 72%, respectively, compared to a reduction of 32% and 29% for those receiving cognitive behavioral therapy with placebo. The use of N-acetyl cysteine did not impact the intensity of cravings or the actual rate of substance use during the study, which was low for all patients (97037).
Postmenopausal conditions. It is unclear if oral N-acetyl cysteine is beneficial for preventing postmenopausal bone loss. Details: One small clinical trial shows that taking N-acetyl cysteine 2 grams daily for 3 months does not reduce postmenopausal bone loss when compared with placebo (64576).
Preterm labor. It is unclear if oral N-acetyl cysteine is beneficial for reducing the risk for preterm labor. Details: Some clinical research shows that taking N-acetyl cysteine 0.6 grams daily orally in combination with 17-hydroxyprogesterone caproate (17-OHPC), beginning at 16 to 18 weeks gestation and continuing until active labor, increases the likelihood of reaching 36 weeks gestation and increases gestational age at delivery in adults with previous preterm labor and bacterial vaginosis when compared with 17-OHPC alone (64615). However, taking oral N-acetyl cysteine 0.6 grams every 8 hours, beginning at 25 to 33 weeks gestation and continuing until delivery, does not improve the treatment-to-delivery interval when compared with placebo in adults with early onset severe pre-eclampsia and/or HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome (64493).
Radiation-induced sialadenitis. It is unclear if mouthwash containing N-acetyl cysteine is beneficial for reducing dry mouth during chemoradiotherapy. Details: One clinical trial in a small group of patients undergoing chemoradiotherapy for head and neck cancer shows that using a mouth rinse containing N-acetyl cysteine 500 mg five times daily during radiotherapy and 2 weeks postradiotherapy improves daytime and total sticky saliva and feelings of dry mouth by up to 38% when compared with placebo. However, N-acetyl cysteine does not seem to improve nighttime symptoms (102661).
Schizophrenia. Oral N-acetyl cysteine seems to improve negative symptoms of schizophrenia. The benefits of N-acetyl cysteine on positive symptoms of schizophrenia are less clear. Details: A meta-analysis of clinical research shows that taking N-acetyl cysteine for at least 6 months has a small to moderate effect on negative symptoms when compared with placebo. However, taking N-acetyl cysteine for only 8 weeks does not reduce negative symptoms, suggesting that a longer duration of treatment may be necessary (102658). Individual clinical studies show that N-acetyl cysteine does not improve positive symptoms, social function, cognition, and clinical global impression when compared with placebo (64605,99528). However, a meta-analysis of available research shows that taking N-acetyl cysteine for any duration has a small effect on positive symptoms, a moderate effect on working memory, and a large effect on overall symptoms (102658). It is possible that many individual studies were underpowered to detect a difference.
Sepsis. Small clinical studies suggest that intravenous N-acetyl cysteine may improve respiratory function and tissue oxygenation, but not mortality, in patients with septic shock. Details: Two small clinical studies show that intravenous N-acetyl cysteine might improve respiratory function and tissue oxygenation, but not mortality, in some patients with recently diagnosed septic shock when compared with placebo (64760,64797).
Sjogren syndrome. Small clinical studies suggest that oral N-acetyl cysteine may improve ocular and oral manifestations of this condition. Details: Two small clinical studies in adults with Sjogren syndrome show that taking oral N-acetyl cysteine 200 mg three times daily for 4 weeks reduces eye soreness and irritability, bad breath, and daytime thirst when compared with a control group; however, objective signs of dry eye were not improved (64673,64812).
Systemic lupus erythematosus (SLE). It is unclear if oral N-acetyl cysteine is beneficial in patients with SLE. Details: One small clinical trial shows that taking N-acetyl cysteine orally 2.4-4.8 grams daily for 3 months significantly reduces disease activity and fatigue when compared with placebo in patients with SLE (91242).
Thrombocytopenia. Oral N-acetyl cysteine has only been evaluated in combination with other ingredients, its effect when used alone is unclear. Details: A very small clinical study in adults with primary immune thrombocytopenia resistant or refractory to steroid therapy shows taking N-acetyl cysteine 400 mg every 8 hours with atorvastatin daily for at least one month at least doubles platelet count or increases it above 30 × 109/L compared to baseline in 60% of participants. However, 40% of participants did not respond to treatment (111572). It is unclear if this effect is due to N-acetyl cysteine, atorvastatin, or the combination. The validity of these findings is limited by the very small sample size, insufficient randomization, lack of a comparator group, and low retention rate, especially in the non-responder group.
Tourette syndrome. It is unclear if oral N-acetyl cysteine is beneficial in patients with this condition. Details: One small clinical trial in children 8-17 years of age with Tourette syndrome shows that taking N-acetyl cysteine 600 mg twice daily for 2 weeks, followed by 1200 mg twice daily for the next 10 weeks, does not improve tic symptoms, premonitory urges, or the comorbid symptoms of obsessive-compulsive disorder (OCD), attention deficit-hyperactivity disorder (ADHD), anxiety, or depression when compared with placebo (97040).
Trichotillomania. Oral N-acetyl cysteine might offer some benefit to adults, but not children, with trichotillomania. Details: One small clinical trial in adults shows that taking N-acetyl cysteine orally, in doses up to 2400 mg daily, significantly decreases the urge to pull hair, the amount of hair pulled, and patients' perception of their control over hair pulling as measured by a self-rating scale. After 12 weeks of treatment, scores decreased by 40% (16840). However, in children, taking N-acetyl cysteine in doses up to 2400 mg daily for 12 weeks does not seem to improve hair pulling when compared with placebo (91235).
Ulcerative colitis. It is unclear if oral N-acetyl cysteine is beneficial in patients with ulcerative colitis. Details: One small clinical trial shows that oral N-acetyl cysteine 0.8 grams daily in combination with mesalamine 2.4 grams daily for 4 weeks does not improve the rate of clinical remission in individuals with ulcerative colitis when compared with mesalamine alone (64606).
Urinary tract infections (UTIs). Oral N-acetyl cysteine has only been evaluated in combination with other ingredients; its effect when used alone is unclear. Details: Observational research in female breast cancer survivors has found that taking the combination of D-mannose 500 mg, N-acetyl cysteine 100 mg, and Morinda citrifolia fruit extract 200 mg daily for 2 months in addition to antibiotic therapy is associated with reduced recurrence of UTIs and urinary discomfort when compared with antibiotics alone (97360).
Uterine fibroids. It is unclear if oral N-acetyl cysteine is beneficial in patients with uterine fibroids. Details: Preliminary clinical research shows that taking N-acetyl cysteine 600 mg daily for 12 weeks reduces the volume of uterine fibroids by about 25%, compared with a reduction of about 1% with placebo. N-acetyl cysteine also reduces painful and heavy menstrual bleeding when compared with placebo (106889).
Wound healing. It is unclear if postoperative intravenous N-acetyl cysteine is beneficial in patients undergoing lower extremity amputation. Details: A clinical study in patients undergoing lower extremity amputation due to critical limb-threatening ischemia shows that receiving postoperative intravenous N-acetyl cysteine 1200 mg twice daily for 5 days, beginning within 3 hours after surgery, improves tissue perfusion from days 3 to 5 and amputation stump healing at day 30 in patients that are defined as high-risk, but not in the intent-to-treat population, when compared with placebo (108448). The validity of these findings is limited due to the short duration of treatment and the inclusion of both above-the-knee and below-the-knee amputations. More evidence is needed to rate N-acetyl cysteine for these uses.

view details

Safety view details

Interactions with Drugs view details

Below is general information about the interactions of the known ingredients contained in the product NAC. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.

N-ACETYL CYSTEINE (NAC) (NAC)

ACTIVATED CHARCOAL

Interaction Rating = Moderate Be cautious with this combination.

Severity = High • Occurrence = Possible • Level of Evidence = D

N-acetyl cysteine might reduce the effects of activated charcoal, while activated charcoal might reduce the absorption of N-acetyl cysteine.

Details

N-acetyl cysteine appears to reduce the capacity of activated charcoal to adsorb acetaminophen and salicylic acid (7869). Conversely, although clinical research suggests that although activated charcoal can reduce the absorption of N-acetyl cysteine by up to 40%, it does not seem to reduce its clinical effects (1755,22774,22775,64501,64647). Other clinical evidence suggests that activated charcoal does not affect the absorption of N-acetyl cysteine (22776,22777).

ANTICOAGULANT/ANTIPLATELET DRUGS

Interaction Rating = Moderate Be cautious with this combination.

Severity = High • Occurrence = Possible • Level of Evidence = D

Theoretically, N-acetyl cysteine might increase the risk of bleeding when taken with anticoagulant or antiplatelet drugs.

Details

Clinical research suggests that intravenous N-acetyl cysteine decreases prothrombin time, prolongs coagulation time, decreases platelet aggregation, and increases blood loss in surgical patients (64511,64644). Furthermore, in vitro research suggests that N-acetyl cysteine increases the anticoagulant activity of nitroglycerin (22780,64780).

ANTIHYPERTENSIVE DRUGS

Interaction Rating = Moderate Be cautious with this combination.

Severity = Moderate • Occurrence = Possible • Level of Evidence = D

Theoretically, N-acetyl cysteine might increase the risk of hypotension when taken with antihypertensive drugs.

Details

Animal research suggests that N-acetyl cysteine potentiates the hypotensive effects of the angiotensin-converting enzyme inhibitors (ACEIs) captopril and enalaprilat (22785). Theoretically, combining N-acetyl cysteine with other antihypertensive drugs might increase the risk of hypotension.

CHLOROQUINE (Aralen)

Interaction Rating = Moderate Be cautious with this combination.

Severity = Moderate • Occurrence = Possible • Level of Evidence = D

Theoretically, N-acetyl cysteine might interfere with the antimalarial effects of chloroquine.

Details

Animal research suggests that N-acetyl cysteine might reduce the antimalarial effects of chloroquine by increasing cellular levels of glutathione (22786).

NITROGLYCERIN

Interaction Rating = Major Do not take this combination.

Severity = High • Occurrence = Probable • Level of Evidence = B

N-acetyl cysteine can increase the risk for hypotension and headaches when taken with intravenous or transdermal nitroglycerin.

Details

Clinical research shows that concomitant administration of N-acetyl cysteine and intravenous or transdermal nitroglycerin can cause severe hypotension (2246) and intolerable headaches (2245,2280). Furthermore, in vitro research suggests that N-acetyl cysteine increases the anticoagulant activity of nitroglycerin (22780,64780).

view details

Adverse Effects view details

Report an Adverse Reaction to NAC

Below is general information about the adverse effects of the known ingredients contained in the product NAC. Some ingredients may not be listed. This information does NOT represent a recommendation for or a test of this specific product as a whole.

N-ACETYL CYSTEINE (NAC) (NAC)

General ...Orally, intravenously, and as an inhalation, N-acetyl cysteine is generally well-tolerated when used in typical doses. Most adverse effects to N-acetyl cysteine occur when single doses of greater than 9 grams are used or when a regimen of greater than 30 grams daily is followed.
Most Common Adverse Effects:
Orally: Diarrhea, dry mouth, dyspepsia, heartburn, loss of appetite, nausea, and vomiting.
Intravenously: Skin rash and hypersensitivity reactions.
Inhaled: Bronchospasm, cough, epigastric pain, throat irritation, and wheezing.
Serious Adverse Effects (Rare):
Orally: Chest tightness, hemoptysis, and palpitations have been reported.
Intravenously: Anaphylaxis, angina, dystonic reactions, tachycardia, and transient sinus bradycardia have been reported.

Cardiovascular ...Intravenously, N-acetyl cysteine has been reported to significantly increase systolic and diastolic blood pressure after exposure to nitroglycerin when compared with placebo (2280). Tachycardia, chest pain, angina, and transient sinus bradycardia have been rarely reported after administration of intravenous N-acetyl cysteine (2280,7872,64658).
Intratracheally, infants receiving 5% N-acetyl cysteine every four hours for chronic lung disease have developed bradycardia (64490).
Orally, palpitations and chest tightness have been reported rarely in clinical research evaluating oral N-acetyl cysteine at doses up to 600 mg twice daily (64675,64717,64762).

Dermatologic ...Orally, N-acetyl cysteine may cause hives (64713,64739,64813), flushing (2260,64715), and edema (64714). Rash has also been reported (64510,64715,64717,102656). In one study, flushing was reported in 2% of patients receiving 600 mg of N-acetyl cysteine orally twice daily for six months (2260).
Intravenously, N-acetyl cysteine may cause rash, and the occurrence seems to be more common than with oral use (2254,64492,64562,64658,64759,64794). Hives (2280,64794), facial edema (2280), flushing (64412), and pruritus (64658,64763) have also been reported. In a small case series of 10 healthy male patients receiving 150 mg/kg of intravenous N-acetyl cysteine for muscle fatigue, erythema was experienced 30 minutes after infusion. Other side effects reported by these patients include facial erythema, palmar erythema, and sweating (64763). In other clinical research, three patients developed an erythematous flare at the sites of previous venipunctures after receiving 5.5 gm/m2 of N-acetyl cysteine with doxorubicin therapy (64712). Pain, inflammation, and excoriation of the skin have been reported after a 20% N-acetyl cysteine solution leaked from the catheter in one patient (64726).

Gastrointestinal ...Orally, gastrointestinal complaints are the most common adverse effects reported with N-acetyl cysteine. These include heartburn (64608,64715,64717,64738,64739,102666), dyspepsia (1710,64715,64717,64724,64738), and epigastric pain (2260,10429,64715,64717). In one case report, esophagitis related to ulcerations occurred following intake of N-acetyl cysteine while in the supine position with inadequate water (102655). Other common side effects include loss of appetite (64715,64812), flatulence (2256,64510), diarrhea (64713,64715,97049), constipation (64715), dry mouth (64715,64724), nausea (7868,11430,64715,64724,64738,64812,97049), vomiting (64717,64724,64715,97049), gastric upset (64510,64545,97045,97049), acid reflux (108450), changes in bowel habits (108450), and intolerance to taste and odor (64510,64545). N-acetyl cysteine's unpleasant odor makes it difficult for some patients to take orally. Using a straw to drink N-acetyl cysteine solutions can improve tolerability. Additionally, placement of a nasogastric or duodenal tube and administration of metoclopramide or ondansetron can be helpful for patients unable to tolerate oral N-acetyl cysteine (17).
Intravenously, N-acetyl cysteine may cause diarrhea (64712), dyspepsia, nausea, vomiting (64763), mild gastrointestinal upset (102657), and metallic taste (64763).
When inhaled, N-acetyl cysteine may cause epigastric pain and throat irritation (64703,64707,64674).

Genitourinary ...Orally, dysuria was reported in 2% of patients receiving 600 mg of N-acetyl cysteine twice daily for 6 months in one clinical trial (2260).

Hematologic ...In general, hematologic adverse reactions are reported more frequently with intravenous N-acetyl cysteine compared with oral use. In surgical patients, decreased prothrombin time (1341,64511), prolonged coagulation time (64511), increased blood loss (64511,64644), and decreased platelet aggregation (64511) have been reported after administration of IV N-acetyl cysteine. In one clinical trial, six healthy patients were administered a loading dose of IV N-acetyl cysteine 10 mg/kg followed by 10 mg/kg per hour for 32 hours. All patients experienced a decrease in prothrombin time by 30% to 40%. The decrease prothrombin time (25.4 sec to 20.6 sec) reached a steady state after 16 hours (1341). In a clinical trial evaluating patients with acute myocardial infarction, hemorrhage occurred in three patients taking intravenous N-acetyl cysteine 10 mg/min, heparin (per study protocol), and aspirin (7872). Two pediatric patients receiving intravenous N-acetyl cysteine (loading dose: 140 mg/kg followed by 70 mg/kg) experienced episodes of coagulopathy; however, patients were being treated for acetaminophen overdose (64794).
Hemoptysis was reported in six patients receiving 200 mg of N-acetyl cysteine orally twice daily for 6 months for treatment of chronic bronchitis (64739).

Immunologic ...Orally, anaphylaxis to N-acetyl cysteine has been rarely reported (64794). However, anaphylactic reactions to intravenous N-acetyl cysteine appear to be more common (1716,64412,64449,64628,64710,64711,64721,64786,64789).
Anaphylactic reactions to N-acetyl cysteine have involved rash, angioedema, hypotension, and bronchospasm (64449,64711,64720). The mechanism of this reaction is unclear, but some data suggest it is not an immunologic hypersensitivity reaction but rather an acute toxic effect of N-acetyl cysteine (64786,64641,64720). Management guidelines for the treatment of anaphylactoid reactions to intravenous N-acetyl cysteine have been published. In most cases, treatment is not required or treatment with diphenhydramine or salbutamol is sufficient to continue or restart N-acetyl cysteine infusion. Antihistamines are useful in controlling and preventing recurrence of anaphylactoid symptoms (1716).

Musculoskeletal ...In one clinical trial, joint pain was reported in more than 15% of patients receiving oral N-acetyl cysteine (64608). In other research, one patient experienced pain in the legs while taking 600 mg of N-acetyl cysteine twice daily for the treatment of chronic bronchitis (64762).

Neurologic/CNS ...Orally, headache has been frequently reported with N-acetyl cysteine in clinical research (7873,11430,64510,64608,64672,64713,64715,64724,64762). Other less common adverse effects reported in patients taking oral N-acetyl cysteine at a total daily dose of 600-1200 mg include dizziness (64715,64717,64724,64762), tiredness (64675,64717), vivid dreams (102666), disorientation, and inability to concentrate (64673). One pediatric patient receiving oral N-acetyl cysteine (loading dose: 140 mg/kg followed by 70 mg/kg) experienced encephalopathy (64794).
Intravenously, N-acetyl cysteine has been associated with rare neurologic adverse reactions , including headache (7872), lightheadedness (64763), and dystonic reactions (64794). In a previously healthy 2-year-old female, status epilepticus occurred during intravenous N-acetyl cysteine therapy for paracetamol ingestion (64781). Increased deterioration in bulbar function in patients with amyotrophic lateral sclerosis has also been reported with IV N-acetyl cysteine (2254).

Ocular/Otic ...While rare, blurred vision has been reported in research on oral N-acetyl cysteine (64715). Additionally, in a previously healthy 2-year-old female, status epilepticus followed by cortical blindness occurred during intravenous N-acetyl cysteine therapy for paracetamol ingestion. In this case, vision was almost completely recovered 18-months later (64781).

Psychiatric ...Intravenously, dysphoria was experienced 30 minutes after infusion of N-acetyl cysteine in 8 of 10 healthy males assessed in one clinical study (64763).

Pulmonary/Respiratory ...Respiratory adverse reactions to N-acetyl cysteine are most commonly reported with inhalable dosage forms. These include wheezing (64455,64707), bronchospasm (64455,64699), and cough (64455,64456,64703,64811). While less frequent, wheezing (64675), bronchospasm (64675), increased sputum production (7868), cough (7868,64510), decreased peak flow (64510), dyspnea (64714), and cold symptoms (64510) have been reported with oral N-acetyl cysteine in clinical research. A few cases of wheezing (64718,64719), cough (64763), and bronchospasm (64658) have also been reported with intravenous N-acetyl cysteine. Additionally, respiratory arrest has been reported in one case where a 16 year-old female was being treated for acetaminophen toxicity with intravenous N-acetyl cysteine (64450).
Two premature infants receiving 5% N-acetyl cysteine via intratracheal instillation for the treatment of chronic lung disease had an increased frequency of cyanotic spells (64490).

Other ...Injection site reactions, including burning and phlebitis, have been reported in patients receiving IV N-acetyl cysteine (1341,64763). Fever associated with IV N-acetyl cysteine was reported in one patient during clinical research (64759).

Report an Adverse Reaction to NAC

view details